{"filings":[{"id":2033957,"accession_number":"0001274737-26-000047","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-08-04T12:02:40+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.","Adjusted EBITDA loss narrowed to $0.1M from $1.7M; operating loss $1.7M vs $2.6M.","AVISE CTD test volume +11% YoY; trailing 12-month ASP $446, up $18 (+4%).","Full-year 2026 revenue guidance raised to $72-75M from prior $70-73M.","Cash $24.6M; published study showing AVISE Lupus identified ~25% of SLE patients missed by conventional markers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945716,"accession_number":"0001274737-26-000033","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-06-09T20:14:00+00:00","items":["5.07"],"status":"ready","headline":"Exagen shareholders re-elect two Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Tina S. Nova re-elected with 8,094,349 votes for (97.3% of votes cast); Dr. Scott Kahn with 6,295,837 (75.7%).","Ratified BDO USA as independent auditor for FY 2026 (16,955,368 for, 4 against, 23,277 abstain).","Advisory vote on named executive officer compensation approved (8,271,156 for, 22,870 against, 21,277 abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91857,"accession_number":"0001274737-26-000027","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose 12% YoY to $17.3M; net loss widened to $4.0M from $3.8M.","AVISE CTD test volume increased 10% YoY; TTM ASP rose 6% to $444.","Adjusted EBITDA loss improved 14% to $2.2M; cash $21.5M, ahead of expectations.","Full-year 2026 revenue guidance reaffirmed at $70M-$73M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":17306000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91856,"accession_number":"0001274737-26-000015","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Ana Hooker resigns from Exagen board, effective April 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ana Hooker resigned as director and chair of Nominating and Corporate Governance Committee, also member of Audit Committee.","Resignation was not due to any disagreement with Exagen on operations, policies, or practices.","Board size reduced from 8 to 7 members effective April 17, 2026.","Paul Kim, Scott Kahn, Bruce Robertson, Frank Stokes, Charles McKhann remain with updated committee assignments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102237,"accession_number":"0001274737-26-000007","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY 2025 revenue of $66.6M, up 20% YoY; guides FY 2026 revenue $70-73M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $66.6M (+20% YoY); Q4 2025 revenue $16.6M.","Full-year net loss $19.95M; adjusted EBITDA loss $9.79M; gross margin 58.3%.","AVISE CTD test volume grew >11% YoY; trailing 12-month ASP rose to $441 (+7%).","FY 2026 revenue guidance of $70M to $73M; path to cash flow positivity.","Year-end cash $32.4M; strengthened by $20M equity offering and $25M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102236,"accession_number":"0001274737-26-000003","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exagen reports record 2025 revenue $66-67M, up 19-20% YoY; cash at $32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $16-17M (17-24% YoY growth); full-year revenue $66-67M (19-20% YoY growth).","AVISE CTD volume 136,000-137,000 (+11% vs 2024); TTM ASP $441-$445, up >$30 from 2024.","Year-end cash $32M, up $10M from 2024; results in line with prior guidance.","CEO cites topline growth from volume and ASP expansion; new AVISE platform enhancements launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":66575000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118540,"accession_number":"0001274737-25-000069","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 revenue $17.2M (+38% YoY), record; net loss $7.1M; guides FY rev $65-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.2M up 38% YoY; net loss $7.1M vs $5.0M loss last year.","Adjusted EBITDA loss narrowed to $1.9M from $4.0M; gross margin improved to 58.4%.","AVISE CTD test volume up 16% YoY; ASP $441 (+$37 YoY).","Cash at $35.7M, up from $30.0M in Q2 2025.","FY2025 revenue guidance $65-70M; expects positive adjusted EBITDA in Q4 at high end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":49944000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135013,"accession_number":"0001274737-25-000061","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.","Net loss $4.4M vs $3.0M in Q2 2024; operating loss $2.6M, roughly flat; adjusted EBITDA -$1.7M.","Cash $30.0M after $20.2M public offering and new credit facility; ASP $428, up $27 YoY.","FY 2025 revenue guidance $65M-$70M; expects positive adjusted EBITDA in Q4 at high end.","Appointed Dr. Michael Mahler as CSO; added Chas McKhann to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":32700000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135012,"accession_number":"0001274737-25-000055","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints former Silk Road Medical CEO Chas McKhann to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chas McKhann appointed Class III director effective July 17, 2025; term expiring at 2028 annual meeting.","Previously served as President/CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific.","Board size increased from 7 to 8 members; McKhann also joins Compensation and Nominating Committees.","McKhann received 7,500 RSUs vesting over 4 years; annual option for 9,000 shares under amended compensation plan.","Board approved amended non-employee director compensation program effective July 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151959,"accession_number":"0001274737-25-000036","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Aballi re-elected with 8.59M votes; Bruce Robertson re-elected with 5.66M votes for three-year terms.","BDO USA ratified as auditor for FY2025 (11.53M for, 74,611 against).","Advisory vote on executive compensation approved (8.60M for); frequency set at 1 year (8.38M for).","Broker non-votes of ~3.0M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151958,"accession_number":"0001193125-25-116881","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exagen closes $20.2M public offering at $5.25/share; net proceeds ~$18.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,350,000 shares plus full exercise of underwriter's option for 502,500 shares.","Gross proceeds of ~$20.2M; net proceeds after fees and expenses ~$18.6M.","Canaccord Genuity acted as sole bookrunner; offering priced at $5.25 per share.","Shares sold under effective shelf registration; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151957,"accession_number":"0001193125-25-115946","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Exagen prices public offering of 3.35M shares at $5.25/share for ~$17.6M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,350,000 shares priced at $5.25; gross proceeds $17.6M; net expected ~$16.2M after expenses.","Underwriter Canaccord Genuity has a 30-day option to buy up to 502,500 additional shares.","Offering expected to close May 9, 2025; proceeds for working capital and general corporate purposes.","All shares sold by Exagen; no binding acquisition agreements at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151956,"accession_number":"0001274737-25-000023","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 revenue record $15.5M, but net loss widens to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.5M (+7.5% YoY); net loss $(3.8)M vs $(3.4)M; adjusted EBITDA $(2.5)M vs $(2.0)M.","Trailing-12-month ASP rose to $419 from $377; AVISE CTD test volume grew.","FY2025 guidance: revenue at least $65M; targeting positive adjusted EBITDA in Q4 2025.","Closed $25M senior secured credit facility with Perceptive Advisors on April 25, 2025.","Combined cash and AR projected ~$28M as of April 30 after releasing held claims."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":15498000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151955,"accession_number":"0001193125-25-100447","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Exagen secures up to $75M term loan from Perceptive; $25M funded to retire existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M funded at closing used to retire Innovatus debt; net proceeds ~$22.8M after costs.","Additional tranches: $10M (by Mar 2026), $10M (by Dec 2026), $30M (BD by Mar 2027) subject to revenue milestones.","Interest: Term SOFR + 7% (floor 4.75%), interest-only for 60 months, maturity April 25, 2030.","Warrants for 400k shares issued at close (exercise $4.96/$5.58); up to 750k more for future tranches.","Loan secured by substantially all assets; covenants include $3M min cash and quarterly net revenue targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170801,"accession_number":"0001274737-25-000018","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.","AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.","FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).","Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.","Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170800,"accession_number":"0001274737-25-000003","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.","Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).","AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.","Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.","CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":55641000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187772,"accession_number":"0001274737-24-000091","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.","AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.","Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.","Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.","Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":41986000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204278,"accession_number":"0001274737-24-000078","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen posts record Q2 revenue $15.1M, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue of $15.1M in Q2 2024, up from $14.1M in Q2 2023.","Net loss improved 40.8% to $3.0M; adjusted EBITDA loss improved 53.5% to $1.6M.","Gross margin expanded to 60.1% from 58.7% YoY.","AVISE CTD trailing 12-month ASP reached $401, up 25.3% YoY.","Company raised full-year 2024 revenue and adjusted EBITDA guidance (specific figures not disclosed in release)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":29479000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204277,"accession_number":"0001274737-24-000071","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.","John Aballi serves as interim CFO from July 31 until Black's start.","Black receives $460K base salary, $125K signing bonus, and up to 225K RSUs.","Black previously CFO at Standard BioTools, Apollo Endosurgery, and Alphatec Spine.","Adawi entitled to severance as Tier 2 participant under company's severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204276,"accession_number":"0001274737-24-000074","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K/A","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Jeffrey Black as CFO effective Sept 1, John Aballi interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kamal Adawi terminated as CFO and Corporate Secretary effective August 1, 2024.","John Aballi named interim CFO and principal financial officer pending Black's start.","Jeffrey Black to become CFO on Sept 1, 2024; base salary $460K, signing bonus $125K.","Black receives RSUs for 225,000 shares vesting over 4 years, target bonus 50% of salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221022,"accession_number":"0001274737-24-000056","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen stockholders elect three Class II directors and ratify BDO USA as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ana Hooker, Paul Kim, Frank Stokes elected as Class II directors for three-year term expiring 2027.","Kim received 8,037,137 votes for; Hooker 7,720,706; Stokes 7,970,534; broker non-votes 3,839,742 each.","Ratification of BDO USA as independent auditor passed with 11,798,192 for, 19,271 against, 81,801 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221021,"accession_number":"0001274737-24-000045","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.","Net loss $3.4M, a 56.3% improvement; adjusted EBITDA -$2.0M, a 67.7% improvement.","AVISE CTD trailing 12-month ASP $377, up 35.1% versus prior year.","Company raises full-year 2024 revenue and adjusted EBITDA guidance on strong momentum.","Cash and equivalents $27.3M; accounts receivable $10.9M; cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":14415000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221020,"accession_number":"0001274737-24-000030","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Scott Kahn to board; three directors resign, board size reduced to 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Brian Birk, Wendy Johnson, and Ebetual Pallares to resign effective June 10, 2024; no disagreements cited.","Scott D. Kahn, Ph.D. appointed as Class I director effective June 10, 2024; serves on Compensation and Nominating Committees.","Board size decreases from 9 to 7 members at the effective date.","Dr. Kahn brings 30+ years life sciences experience, including former CIO at Illumina and Chief Information/Privacy Officer at LunaPBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240602,"accession_number":"0001274737-24-000019","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY2023 revenue of $52.5M; net loss narrows to $23.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record full-year revenue $52.5M (+10% YoY); Q4 revenue $13.8M (+8% YoY)","Record 137,650 AVISE CTD tests performed in 2023; trailing 12-month ASP rose to $336","Gross margin improved to 56% for FY2023 (59% Q4) from 44% in FY2022","Net loss $23.7M for FY2023 vs $35.1M in FY2022; adjusted EBITDA -$17.1M vs -$29.1M","Cash balance $36.5M at year-end; management cites progress toward profitability"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240601,"accession_number":"0001274737-24-000006","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record AVISE CTD volume of ~137k units, reaffirms FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record AVISE® CTD testing volume of approx. 137,000 units in FY2023.","Cash balance of $36.5M as of Dec 31, 2023; AR approx. $7M.","Reaffirms FY2023 revenue guidance of at least $50M, non-GAAP adjusted EBITDA of approx. -$20M.","Management points to streamlined operations and revamped expense structure toward profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":52548000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258108,"accession_number":"0001274737-23-000116","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chief Business Officer Mark Hazeltine resigns; enters consulting and severance agreements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Hazeltine resigned as CBO on Dec 6, 2023; will provide consulting through Mar 31, 2024 at $243/hour.","Severance includes $202,442 (6 months salary) and $182,197 (100% of 2023 performance bonus).","Unvested stock options and RSUs continue to vest during consulting term.","Company eliminated the CBO position; consulting includes knowledge transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258107,"accession_number":"0001274737-23-000105","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Exagen amends ATM facility with I.B.6 float limitation; $50M capacity unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds General Instruction I.B.6 limit: sales capped at one-third of public float per any 12-month period while float below $75M.","Total at-the-market equity offering capacity remains at up to $50 million.","No shares have been sold under I.B.6 in the prior 12-month period ending Nov 17, 2023.","Amendment dated November 17, 2023, with TD Cowen (formerly Cowen and Company, LLC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258106,"accession_number":"0001274737-23-000101","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.","Adj. EBITDA improved to $(3.6)M from $(6.1)M YoY; gross margin 57.4% vs 59.2%.","Cash $28.4M at Sep 30, $31.4M at Oct 31; AVISE CTD ASP $320.","FY 2023 guidance: rev ≥$50M (record), adj. EBITDA ~$(20)M; expects improvement in 2024.","Exclusive license with Johns Hopkins to develop lupus nephritis biomarkers."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":38783000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258105,"accession_number":"0001274737-23-000096","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Exagen assigns lease for 1221 Liberty Way to Mindera; released from obligations with $65K deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exagen assigned its lease for office space at 1221 Liberty Way, Vista, CA to Mindera Corporation.","Exagen continues rent and expense obligations until Oct 31, 2023; thereafter Mindera assumes them.","Landlord releases Exagen from all lease obligations upon receipt of $65,000 additional security deposit.","Lease originally dated August 15, 2014; assignment executed October 24, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275422,"accession_number":"0001274737-23-000085","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q2 revenue $14.1M, record AVISE CTD tests; net loss narrows to $5.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.1M, up 26% QoQ from $11.2M (Q1 2023) and up from $7.6M (Q2 2022).","Record 37,749 AVISE CTD tests (+8% YoY); trailing 12-month ASP $320.","Gross margin 58.7% (Q2 2023) vs 20.1% (Q2 2022); net loss $5.0M vs $14.7M loss a year ago.","Q3 2023 revenue guidance $10M-$10.5M; cash $31.5M as of June 30, 2023.","Operating expenses $19.1M, down from $21.7M due to December 2022 headcount reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":25367000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275421,"accession_number":"0001274737-23-000074","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Paul Kim to board of directors; Kim is CFO of Fulgent Genetics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Kim appointed to Exagen board as Class II director effective July 24, 2023.","Kim also appointed to Audit Committee and Compensation Committee.","Kim has served as CFO of Fulgent Genetics (FLGT) since 2016; previously CFO of Cogent, Inc.","Kim received option to purchase 15,000 shares vesting over 3 years; standard director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292916,"accession_number":"0001274737-23-000067","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen stockholders re-elect Birk, Nova, Pallares; ratify BDO USA auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brian Birk re-elected with 10,235,097 votes for; 412,248 withheld; 2,862,201 broker non-votes.","Tina S. Nova, Ph.D. re-elected with 10,515,263 votes for; 132,082 withheld; same broker non-votes.","Ebetuel Pallares, Ph.D. re-elected with 10,306,011 votes for; 341,334 withheld; same broker non-votes.","Ratification of BDO USA LLP as auditor for FY2023: 13,481,521 for, 2,643 against, 25,382 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292915,"accession_number":"0001274737-23-000046","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1: record 37,312 AVISE CTD tests, revenue $11.2M (+8% YoY), net loss narrows to $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Delivered 37,312 AVISE CTD tests (+21% YoY); Q2 2023 revenue guided $10.7-11.2M.","Total revenue $11.2M (+8% YoY); gross margin improved to 47.2% from 44.0%.","Operating expenses $18.9M (-5.7% YoY); net loss $7.7M vs. $10.3M loss in Q1 2022.","AVISE CTD trailing 12-month ASP $279; cash and equivalents $52.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":11230000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292914,"accession_number":"0001274737-23-000041","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Exagen amends loan with Innovatus: $10M prepaid, interest-only extended, revenue covenants eased","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepaid $10M principal; prepayment fee waived.","Interest rate: prime (floor 8%) + 2%, with 1.5% payable-in-kind (PIK) through Apr 2026.","Interest-only period extended to March 2026; maturity extended to Dec 31, 2026.","Revenue covenant thresholds reduced; can be bypassed if cash balance ≥50% of loan principal.","Added 30-day cure period for covenant breaches; broadened permitted indebtedness limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313580,"accession_number":"0001274737-23-000024","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exagen board member James Tullis to resign at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James L.L. Tullis notified Board on March 20, 2023 of resignation effective at the 2023 annual meeting.","Resignation is not due to any disagreement with the Company or Board.","No replacement has been announced for the departing director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313579,"accession_number":"0001274737-23-000017","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q4 net loss $14.4M on $5.5M goodwill impairment; Q1 revenue guidance raised to $9.2-9.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record 135,210 AVISE CTD tests in 2022; 33,819 in Q4; cumulative ~750,000 since 2012 launch.","Q4 revenue $12.8M (+0.8% YoY); gross margin fell to 50.9% from 61.1% on inflation and mix.","Full-year 2022 net loss $47.4M vs $26.9M in 2021; operating expenses rose to $91.6M.","New CEO John Aballi joined Q4 2022; strategy focuses on reducing cash burn and reaching profitability.","Q1 2023 revenue guidance raised to $9.2-9.7M from prior $8.2-9.2M range."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313578,"accession_number":"0001274737-23-000004","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Exagen appoints Tina S. Nova, Ph.D. as Executive Chair, effective Jan 19, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Nova replaces Brian Birk, who remains on the Board.","Nova is President of Veracyte's U.S. CLIA business; former CEO of Decipher Biosciences.","Nova co-founded Genoptix (sold to Novartis for $470M) and held leadership at Illumina.","Company says her experience will help expand its position in autoimmune testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313577,"accession_number":"0001274737-23-000002","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Exagen provides preliminary Q4 and FY 2022 AVISE CTD unit volumes, Q1 2023 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Delivered ~33,800 AVISE CTD units in Q4 2022; ~135,000 units for full year 2022.","Expects Q1 2023 revenue between $8.2M and $9.2M.","Estimates profitability achievable at $75M annual revenue assuming 60% gross margin."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":45563000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332049,"accession_number":"0001274737-22-000080","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["2.05","5.02","9.01"],"status":"ready","headline":"Exagen reduces workforce by 42, estimates $750k in Q4 charges; CMO terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction in force of 42 employees, completed Dec 5, 2022, to conserve cash.","Estimated pre-tax charges of ~$750k in Q4 2022 for severance, benefits, and related costs.","CMO Debra Zack terminated; entitled to lump sum of ~$201.6k (6 months salary) plus COBRA reimbursement.","Dr. Zack entered consulting agreement at $250/hr through Mar 31, 2023; unvested stock options continue to vest.","COO Mark Hazeltine appointed Chief Business Officer, effective Dec 5, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332048,"accession_number":"0001274737-22-000070","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Exagen restates Q2 2022 financials for revenue errors; Q3 revenue $14.7M, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Audit Committee determined revenue recognition errors: revenue overstated $1.4M, AR overstated $0.9M, liabilities understated $0.5M for Q2 2022.","Q3 2022 revenue $14.7M (vs $12.3M in Q3 2021); net loss $8.1M (vs $7.2M loss).","Full-year 2022 revenue guidance raised to $40-43M from prior range; Medicare resumed AVISE Lupus payments dating to Q2.","John Aballi appointed President and CEO, effective with Q3 earnings release.","Company expects to report at least one material weakness in internal controls over financial reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":32726000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332047,"accession_number":"0001274737-22-000067","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Exagen names John Aballi CEO, succeeding Ron Rocca who resigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.","Aballi previously SVP/GM Urology and CLIA COO at Veracyte; grew urology unit to $120M+ revenue annually.","Aballi receives base salary $525,000, target bonus 50% of base, equity award of 350,000 shares/units vesting 4 years.","Ron Rocca severance: lump sum $424,875, pro-rated incentive compensation, and 9 months COBRA reimbursement.","Rocca's resignation not due to any disagreement with company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349518,"accession_number":"0001274737-22-000064","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Exagen enters $50M ATM equity offering with Cowen and Company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows Exagen to sell up to $50M of common stock at market prices via Cowen as agent.","Cowen receives 3% commission on gross proceeds; Company not obligated to sell any shares.","Offering terminates upon sale of all shares or termination of the agreement.","Shares sold through Nasdaq Global Market; prospectus supplement filed September 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349517,"accession_number":"0001274737-22-000051","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q2 revenue $9.0M, net loss $13.3M; cuts 2022 guidance to $35-40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["AVISE CTD volume hit record 34,919 tests, up 5% YoY and 13% sequentially.","Revenue fell to $9.0M from $12.8M YoY; gross margin dropped to 32.2% from 57.3%.","Net loss widened to $13.3M from $6.4M loss in Q2 2021.","2022 revenue guidance revised to $35-40M, citing Medicare reimbursement uncertainty.","Record 2,273 ordering providers and 797 adopters; ~100M in-network lives under contract."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":19356000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366489,"accession_number":"0001274737-22-000039","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen stockholders elect three Class III directors and ratify BDO as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Bruce Robertson, Wendy Johnson, Fortunato Ron Rocca; each received ~8.1M votes for, ~520k withheld, 1.41M broker non-votes.","Ratification of BDO USA as independent auditor approved: 10,044,739 for, 3,120 against, 32,803 abstentions.","Annual meeting held June 16, 2022; three director terms expire at 2025 annual meeting.","Proposal details were in the definitive proxy statement filed April 28, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366488,"accession_number":"0001274737-22-000027","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 revenue $10.4M, net loss widens to $10.3M; raises FY 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 testing revenue $10.4M (flat YoY); total revenue $10.4M vs $10.6M in Q1 2021.","Net loss $10.3M ($0.84 loss per share) vs $6.2M loss a year ago; gross margin fell to 44% from 55.5%.","AVISE CTD test volume 30,903 (+6.5% YoY); record 2,175 ordering healthcare providers and 761 adopters.","FY 2022 revenue guidance raised to $53-55M from $51-53M; cash $89.8M at quarter end.","AMA issued PLA code for AVISE Lupus; Centene/WellCare in-network effective June 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":10394000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366487,"accession_number":"0001628280-22-011111","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Exagen adopts amended executive severance plan with enhanced CIC and non-CIC benefits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan covers CEO Rocca, CFO Adawi, COO Hazeltine, and CMO Debra Zack.","Non-CIC termination: cash severance of 50% (75% for CEO) of base salary plus COBRA for 6 (9 for CEO) months.","CIC termination: cash severance of 100% (125% for CEO) of base salary, COBRA for 12 (15 for CEO) months, and full equity vesting.","Payments require execution of a general release of claims.","Plan effective April 25, 2022; supersedes prior severance arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385943,"accession_number":"0001628280-22-006886","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports FY 2021 revenue up 15% to $48.3M; guides FY 2022 revenue $51-53M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record 128,246 AVISE CTD tests in 2021; Q4 2021 test volume 34,147 (+21% YoY).","Full-year testing revenue $47.1M (+27.8% YoY); Q4 testing revenue $12.5M (+14.2% YoY).","FY 2021 net loss $26.9M vs $16.7M in 2020; cash $99.4M at year-end.","Guidance: FY 2022 revenue $51M-$53M, implying 6-10% growth over 2021.","Added Centene/WellCare coverage for 22M lives; now 91M in-network lives; acquired AVISE RADR license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385942,"accession_number":"0001274737-22-000003","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Exagen provides AVISE RADR presentation; no material operational or financial news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exagen released updated investor presentation highlighting its AVISE RADR test for rheumatoid arthritis drug response.","Presentation dated January 10, 2022, focuses on the test's ability to predict drug response in RA patients.","Company did not disclose any new financial results, guidance, or material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403850,"accession_number":"0001274737-21-000113","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 2021 revenue $12.3M (+14% YoY); net loss widens to $7.2M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.3M, up 14% YoY; AVISE CTD revenue $9.9M (+34% YoY) on 31,742 tests (+21%).","Net loss of $7.2M vs. $4.3M a year ago; operating expenses rose to $18.8M from $14.6M.","Record 1,969 ordering HCPs and 714 adopters; sequential quarterly retention ~99%.","Signed agreement with Inland Empire Health Plan; in-network lives now ~68.9M.","Entered pilot to supply AVISE MTX to retail pharmacy chain & major payor partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":35610000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403849,"accession_number":"0001274737-21-000106","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Exagen refinances $27.2M term loan with Innovatus; maturity extended to Nov 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$27.2M term loan at 8.0% interest (2% paid in-kind) from Innovatus.","Interest-only period extended through December 2024; maturity extended to November 19, 2026.","Financial covenant revised to revenue-based test starting Q4 2022, with cure options via equity or sub debt.","Effective November 1, 2021; press release issued October 25, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-25T23:59:59+00:00|403849"}